• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • Steen Solution™
    • PERFADEX® Plus
    • XVIVO
      Silicone Tubing Set™
    • XVIVO LS™ & XVIVO Disposable Lung Set™
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
    • Movies
  • Media
    • Videos
    • Webinars
  • About us
    • About Xvivo
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO Perfusion
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • CODE OF CONDUCT
    • Privacy policy
    • Subscribe
    • Thank you
    • Error
XVIVO Perfusion
  • Contact us
  • Customer support
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • Steen Solution™
    • PERFADEX® Plus
    • XVIVO
      Silicone Tubing Set™
    • XVIVO LS™ & XVIVO Disposable Lung Set™
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
    • Movies
  • Media
    • Videos
    • Webinars
  • About us
    • About Xvivo
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO Perfusion
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • CODE OF CONDUCT
    • Privacy policy
    • Subscribe
    • Thank you
    • Error
  • Corporate
  • The share
    • Info
    • Ownership structure
    • Insiders (PDMRs)
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • Financial calendar
  • Financial reports
  • Prospectus and material offerings
    • Material offerings
    • Prospectus
  • Financial presentations
  • Corporate governance
    • Article of Association
    • General meetings
    • Board of Directors
    • Senior Management
    • Auditors
    • Board Committees
    • Board and Senior Management share holdings
    • Guidelines for remuneration
    • Nomination Committee
    • Corporate Governance Reports
  • Analyst Coverage
  • CODE OF CONDUCT
  • Privacy policy
  • Subscribe
  • Thank you
  • Error

Interim report January – June 2013

US study has full number of patients and good clinical results presented for patients outside the USA

SIGNIFICANT EVENTS IN THE SECOND QUARTER

• All the planned 42 + 42 patients have now been included in the clinical study of STEEN Solution™ in the USA and the clinical results are very promising.

• At the ISHLT conference in April, three leading clinics outside the USA (Toronto, Paris and Europe’s largest lung transplant clinic in Vienna) presented very good clinical data for 112 patients using XVIVO Perfusion’s product STEEN Solution™. The results show that by using STEEN Solution™ the clinics were able to save many lungs that had initially been assessed as unusable. The lungs were transplanted into patients in need, and the results were at least as good as for lungs initially deemed acceptable.

• During the quarter, the company submitted its response to the FDA’s supplementary questions regarding the application for marketing approval of STEEN Solution™ on the US market. The FDA is expected to notify its decision in the third quarter.

• At the end of June a total of 47 patients in the USA had been transplanted with lungs made available through the use of Steen Solution™ and XVIVO’s perfusion machine XPS™.

FIRST HALF (JAN-JUN 2013)

• Sales increased by 21 percent in local currency. Sales amounted to SEK 32.1 (27.8*) million, corresponding to an increase of 15 percent in SEK.

• Operating income before depreciation and amortization (EBITDA) amounted to SEK 6.1 (9.2*) million, corresponding to an EBITDA margin of 19 percent.

• Net income amounted to SEK 4.1 million, resulting in earnings per share of SEK 0.21.

• Cash flow from operating activities was SEK 7.9 million.

SECOND QUARTER (APR – JUN 2013)

• Sales increased by 18 percent in local currency. Sales amounted to SEK 15.8 (14.0*) million, corresponding to an increase of 12 percent in SEK.

• Operating income before depreciation and amortization (EBITDA) amounted to SEK 2.4 (4.2*) million, corresponding to an EBITDA margin of 15 percent.

• Net income amounted to SEK 1.7 million, resulting in earnings per share of SEK 0.09.

• Cash flow from operating activities was SEK 3.9 million.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Thursday, July 11, 2013.
Telephone: +46 8 50336434 or +44 (0)20 1452 555566, enter code 98290392

* Comparative figures for 2012 are Vitrolife’s Transplantation segment such as it was reported in Vitrolife’s reporting

For further information please contact:

Magnus Nilsson, CEO, tel: 46 31 788 21 50, e-mail: magnus.nilsson@xvivoperfusion.com
Christoffer Rosenblad, CFO, tel: 46 31 788 21 59, e-mail: christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 11, 2013 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

About us

XVIVO Perfusion is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation.

Contact

Swedish Office
XVIVO Perfusion AB
Box 53015
SE-400 14 Göteborg
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivoperfusion.com

Newsletter

I have read and accepted XVIVO Perfusion's Privacy policy

*By signing up to our newsletter you consent to XVIVO Perfusion sending you our insights newsletter and occasional additional communications. Your personal data will be transfered to a third party newsletter distributor engaged by XVIVO Perfusion. All processing of your personal data is in compliance with the XVIVO Perfusion Privacy Policy. For more information on how we use your personal data, please read XVIVO Perfusion’s Privacy policy

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2021 XVIVO Perfusion. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO Perfusion. Read more about Cookies

Approve